Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ketek Launch Is First For Sanofi-Aventis; Merger Will Test Focus

Executive Summary

Ketek will be the first product launch for the newly formed Sanofi-Aventis

You may also be interested in...



Acomplia Launch Could Come This Year, Sanofi-Aventis Says

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) could be launched as early as the end of the year, Exec VP-Pharmaceutical Operations Hanspeter Spek said

Acomplia Launch Could Come This Year, Sanofi-Aventis Says

Sanofi-Aventis' weight loss/smoking cessation agent Acomplia (rimonabant) could be launched as early as the end of the year, Exec VP-Pharmaceutical Operations Hanspeter Spek said

Ketek, Allegra Deserve Special Formulary Status – Aventis Consultants

The ketolide drug class should be added to the U.S. Pharmacopeia's model drug classification system as a unique pharmacologic class, Stephen Jenkins, PhD, Carolinas Medical Center said during an Aug. 27 public meeting on the proposed Medicare Rx formulary guidelines

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel